Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small molecules with EGFR-TK inhibitor activity.

Joan Albanell1, Pere Gascón

  • 1Medical Oncology Department, ICMHO & Unitat de Patologia Mamaria & IDIBAPS. Hospital Clinic, Barcelona, Spain. albanell@clinic.ub.es

Current Drug Targets
|April 29, 2005
PubMed
Summary

Specific EGFR tyrosine kinase inhibitors (TKIs) show promise in treating cancers like NSCLC and pancreatic cancer. Optimizing patient selection through biomarkers like EGFR mutations is key for future TKI development and combination therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer.

Neoplasia (New York, N.Y.)·2026
Same author

Response to the letter to the editor entitled "The precision of a report on precision".

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer.

The Journal of clinical investigation·2025
Same author

Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2025
Same author

TIM3<sup>+</sup> breast cancer cells license immune evasion during micrometastasis outbreak.

Cancer cell·2025
Same author

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial.

NPJ breast cancer·2025

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Specific and reversible EGFR tyrosine kinase inhibitors (TKIs) demonstrate clinical activity in advanced or metastatic non-small cell lung cancer (NSCLC) and pancreatic cancer.
  • Erlotinib is approved for NSCLC post-chemotherapy and shows survival benefits in pancreatic cancer when combined with gemcitabine.
  • Activity is also observed in ovarian cancer and head and neck malignancies, with ongoing or planned Phase III trials.

Purpose of the Study:

  • To explore the clinical development of EGFR TKIs, emphasizing the need for better patient selection criteria.
  • To investigate the potential of newer irreversible EGFR inhibitors, dual EGF/HER2 inhibitors, and pan-ErbB receptor inhibitors.
  • To assess the role of combining TKIs with other therapeutic agents like hormonal agents, biological agents, or chemotherapy.

Related Experiment Videos

Main Methods:

  • Review of clinical activity and ongoing trials of specific and reversible EGFR TKIs.
  • Examination of emerging irreversible EGFR inhibitors, dual inhibitors, and pan-ErbB receptor inhibitors.
  • Analysis of combination therapy studies involving TKIs with other treatment modalities.

Main Results:

  • While effective in selected populations (e.g., EGFR-mutated NSCLC), TKIs show modest activity in unselected patients.
  • Newer generation inhibitors (irreversible, dual, pan-ErbB) may offer greater antitumor activity, requiring further tolerance characterization.
  • Lapatinib (dual EGFR/HER2 TKI) shows promise in breast cancer; novel agents like BMS-599626 are entering clinical trials.

Conclusions:

  • Understanding biological and clinical criteria for patient selection is crucial for optimizing TKI therapy.
  • EGFR mutations and other potential biomarkers can guide patient selection for improved outcomes.
  • Future research directions include evaluating novel inhibitors and combination strategies to enhance efficacy and overcome resistance.